A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated September 27, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
Trial Details
NCT Number NCT06617000
Lead Sponsor SCG Cell Therapy Pte. Ltd.
Conditions
(from sponsor)		 HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov